Association analysis of norepinephrine transporter polymorphisms and methylphenidate response in ADHD patients

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):122-128. doi: 10.1016/j.pnpbp.2018.01.013. Epub 2018 Feb 20.

Abstract

Aims: Methylphenidate (MPH) is the most frequently prescribed drug in Attention Deficit Hyperactivity Disorder (ADHD). Hitherto mostly the dopamine transporter gene has been studied in MPH-response and only a few studies analyzed the norepinephrine transporter (NET, SLC6A2) gene, although MPH is a potent inhibitor of both dopamine and norepinephrine transporters. We aimed to analyze this monoamine transporter gene in relation to ADHD per se and MPH-response in particular to gain further knowledge in ADHD pharmacogenetics using a Caucasian sample.

Methods: Six single nucleotide polymorphisms (rs28386840, rs2242446, rs3785143, rs3785157, rs5569, rs7194256 SNP) were studied across the NET gene in 163 ADHD children (age: 9.3±2.6; 86.5% male) using ADHD-RS hyperactivity-impulsivity and inattention scales. For case-control analysis 486 control subjects were also genotyped. At the MPH-response analysis responders had minimum 25% decrease of ADHD-RS total score after 2months of treatment, and chi-square test compared 90 responders and 32 non-responders, whereas ANOVA was used to assess symptom improvement after the first month among the 122 ADHD patients.

Results: The classical case-control analysis did not yield any association with ADHD diagnosis, which was supported by meta-analysis conducted on the available genetic data (combining previously published and the present studies). On the other hand, the intronic rs3785143 showed nominal association with inattention symptoms (p=0.01). The haplotype analysis supported this association, and indicated the importance of the first haploblock encompassing the intronic and 2 promoter SNPs. With MPH-response only the promoter rs28386840 showed nominal association: Those with at least one T-allele were overrepresented in the responder group (42% vs 19%, p=0.08), and they had better improvement on the hyperactivity-impulsivity scale compared to the AA genotype (p=0.04).

Conclusion: Although none of our single SNP findings remained significant after correcting for multiple testing, our results from the MPH-response analysis indicate the potential importance of promoter variants in the NET gene.

Keywords: ADHD (attention deficit hyperactivity disorder); Methylphenidate; Norepinephrine/noradrenaline transporter, SLC6A2 (solute carrier family 6, member 2); Pharmacogenetics; Promoter polymorphism.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Attention
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / genetics*
  • Case-Control Studies
  • Central Nervous System Stimulants / therapeutic use*
  • Child
  • Female
  • Genetic Association Studies
  • Haplotypes
  • Humans
  • Introns
  • Linkage Disequilibrium
  • Male
  • Methylphenidate / therapeutic use*
  • Norepinephrine Plasma Membrane Transport Proteins / genetics*
  • Pharmacogenomic Variants*
  • Polymorphism, Single Nucleotide
  • Promoter Regions, Genetic

Substances

  • Central Nervous System Stimulants
  • Norepinephrine Plasma Membrane Transport Proteins
  • SLC6A2 protein, human
  • Methylphenidate